ArticleActa crystallographica. Section F, Structural biology and crystallization communications2011
The Protein Maker: an automated system for high-throughput parallel purification.
Article in Acta crystallographica. Section F, Structural biology and crystallization communications, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Optimizing asymmetric antibody purification: a semi-automated process and its digital integration.mAbs · 2025Article
- REVOLVER: A low-cost automated protein purifier based on parallel preparative gravity column workflows.HardwareX · 2022Article
- A multi-column plate adapter provides an economical and versatile high-throughput protein purification system.Protein expression and purification · 2018Article
- Structural basis for therapeutic inhibition of influenza A polymerase PB2 subunit.Scientific reports · 2017Article
- Application of the Protein Maker as a platform purification system for therapeutic antibody research and development.Computational and structural biotechnology journal · 2016Article
- Structural analysis of H1N1 and H7N9 influenza A virus PA in the absence of PB1.Scientific reports · 2014Article
- A structural biology approach enables the development of antimicrobials targeting bacterial immunophilins.Antimicrobial agents and chemotherapy · 2014Article
- Multi-target parallel processing approach for gene-to-structure determination of the influenza polymerase PB2 subunit.Journal of visualized experiments : JoVE · 2013Article
- Structure and function of a cyanophage-encoded peptide deformylase.The ISME journal · 2013Article
- Inhibitor-bound complexes of dihydrofolate reductase-thymidylate synthase from Babesia bovis.Acta crystallographica. Section F, Structural biology and crystallization communications · 2011Article
- Gene design, cloning and protein-expression methods for high-value targets at the Seattle Structural Genomics Center for Infectious Disease.Acta crystallographica. Section F, Structural biology and crystallization communications · 2011Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
The Protein Maker is an automated purification system developed by Emerald BioSystems for high-throughput parallel purification of proteins and antibodies. This instrument allows multiple load, wash and elution buffers to be used in parallel along independent lines for up to 24 individual samples. To demonstrate its utility, its use in the purification of five recombinant PB2 C-terminal domains from various subtypes of the influenza A virus is described. Three of these constructs crystallized and one diffracted X-rays to sufficient resolution for structure determination and deposition in the Protein Data Bank. Methods for screening lysis buffers for a cytochrome P450 from a pathogenic fungus prior to upscaling expression and purification are also described. The Protein Maker has become a valuable asset within the Seattle Structural Genomics Center for Infectious Disease (SSGCID) and hence is a potentially valuable tool for a variety of high-throughput protein-purification applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.